Brief: Oric Pharmaceuticals To Present Preclinical Data On Cd73 Inhibitor Program In Multiple Myeloma At The 64Th American Society Of Hematology (Ash) Annual Meeting
03/11/2022 14:07
Nov 3 (Reuters) - Oric Pharmaceuticals Inc ORIC.O :
* ORIC PHARMACEUTICALS TO PRESENT PRECLINICAL DATA ON CD73
INHIBITOR PROGRAM IN MULTIPLE MYELOMA AT THE 64TH AMERICAN
SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING
Source text for Eikon: ID:nGNX9LgWkM
Further company coverage: ORIC.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on ORIC Pharmaceuticals
See all newsBrief: Oric® Pharmaceuticals Announces Agreement With Cancer Research UK
ORIC Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million
Brief: Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ORIC Pharmaceuticals Q4 loss narrows